Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retlirafusp alfa + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Retlirafusp alfa + nab-paclitaxel is a combination therapy being investigated for the treatment of breast cancer, particularly triple-negative breast cancer (TNBC). Retlirafusp alfa (SHR-A1811) is a next-generation antibody-drug conjugate (ADC) targeting HER2, consisting of a humanized anti-HER2 monoclonal antibody linked to a potent topoisomerase I inhibitor payload (an exatecan derivative) via a cleavable linker. Nab-paclitaxel is an albumin-bound nanoparticle formulation of paclitaxel that inhibits microtubule dynamics. The combination aims to leverage the targeted delivery and bystander effect of the ADC alongside the cytotoxic effects of the taxane to improve outcomes in patients with HER2-expressing or HER2-low breast cancers.
- Other names
- SHR-A1811 plus nab-paclitaxelSHR-A-1811 plus nab-paclitaxelSHR-A 1811 plus nab-paclitaxelretlirafusp alfa plus nanoparticle albumin-bound paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on retlirafusp alfa + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retlirafusp alfa + nab-paclitaxel.